DSaRM meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA's Drug Safety & Risk Management Advisory Committee will convene Feb. 10 to "receive updates on the Drug Safety Oversight Board and agency actions" on COX-2 inhibitors, an announcement in the Federal Register Jan. 6 states. The committee, which will meet from 8 am-3 pm in Gaithersburg, Md., also will be briefed on developments in the Office of Drug Safety. Since the September 2004 market withdrawal of Merck's Vioxx, FDA has hosted a three-day meeting on use of COX-2s and other NSAIDs, as well as required a black box label statement for Pfizer's Celebrex. During a meeting in May, members of the Drug Safety committee advised that FDA make its drug safety process more transparent and consider placing drug safety experts on each of its advisory committees (1"The Tan Sheet" May 30, 2005, p. 9)...
You may also be interested in...
Increased Medication Error Analysis Is Key To Improving Drug Safety – Panel
FDA should enhance its post-market monitoring of drug safety through greater surveillance of medication errors, a member of FDA's Drug Safety & Risk Management Advisory Committee said during a May 19 meeting in Silver Spring, Md
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.